XENON PHARMACEUTICALS INC. Operating Lease Cost
XENON PHARMACEUTICALS INC. (XENE) reported Operating Lease Cost of $389.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-06
- XENON PHARMACEUTICALS INC. operating lease, cost for the quarter ending 2026-06-30 was $389.00K, a 4.89% decline year-over-year.
- XENON PHARMACEUTICALS INC. operating lease, cost for the quarter ending 2026-03-31 was $411.00K, a 0.74% increase year-over-year.
- XENON PHARMACEUTICALS INC. operating lease, cost for the quarter ending 2025-12-31 was $410.00K, a 0.49% decline year-over-year.
- XENON PHARMACEUTICALS INC. operating lease, cost for the quarter ending 2025-09-30 was $411.00K, a 0.00% change year-over-year.
- XENON PHARMACEUTICALS INC. operating lease, cost for fiscal 2025 was $1.64M, a 0.49% decline from fiscal 2024.
- XENON PHARMACEUTICALS INC. operating lease, cost for fiscal 2024 was $1.65M, a 0.06% increase from fiscal 2023.
- XENON PHARMACEUTICALS INC. operating lease, cost for fiscal 2023 was $1.65M, a 46.09% increase from fiscal 2022.
- XENON PHARMACEUTICALS INC. operating lease, cost for fiscal 2022 was $1.13M, a 90.52% increase from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $389.00K 10-Q · filed 2026-08-06 | $800.00K 10-Q · filed 2026-08-06 | $1.21M derived: sum of 3 quarters · filed 2026-08-06 | $1.62M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $411.00K 10-Q · filed 2026-05-07 | $821.00K derived: sum of 2 quarters · filed 2026-05-07 | $1.23M derived: sum of 3 quarters · filed 2026-05-07 | $1.64M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $410.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $821.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.23M derived: sum of 3 quarters · filed 2026-08-06 | $1.64M 10-K · filed 2026-02-26 |
| 2025-09-30 | $411.00K 10-Q · filed 2025-11-03 | $820.00K derived: sum of 2 quarters · filed 2026-08-06 | $1.23M 10-Q · filed 2025-11-03 | $1.64M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $409.00K 10-Q · filed 2026-08-06 | $817.00K 10-Q · filed 2026-08-06 | $1.23M derived: sum of 3 quarters · filed 2026-08-06 | $1.64M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $408.00K 10-Q · filed 2026-05-07 | $820.00K derived: sum of 2 quarters · filed 2026-05-07 | $1.23M derived: sum of 3 quarters · filed 2026-05-07 | $1.64M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $412.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $823.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.23M derived: sum of 3 quarters · filed 2026-02-26 | $1.65M 10-K · filed 2026-02-26 |
| 2024-09-30 | $411.00K 10-Q · filed 2025-11-03 | $822.00K derived: sum of 2 quarters · filed 2025-11-03 | $1.23M 10-Q · filed 2025-11-03 | $1.64M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $411.00K 10-Q · filed 2025-08-11 | $823.00K 10-Q · filed 2025-08-11 | $1.23M derived: sum of 3 quarters · filed 2026-02-26 | $1.65M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $412.00K 10-Q · filed 2025-05-12 | $822.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.23M derived: sum of 3 quarters · filed 2026-02-26 | $1.65M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $410.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $822.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.23M derived: sum of 3 quarters · filed 2026-02-26 | $1.65M 10-K · filed 2026-02-26 |
| 2023-09-30 | $412.00K 10-Q · filed 2024-11-12 | $823.00K derived: sum of 2 quarters · filed 2024-11-12 | $1.24M 10-Q · filed 2024-11-12 | $1.65M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $411.00K 10-Q · filed 2024-08-08 | $823.00K 10-Q · filed 2024-08-08 | $1.24M derived: sum of 3 quarters · filed 2025-02-27 | $1.47M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $412.00K 10-Q · filed 2024-05-09 | $824.00K derived: sum of 2 quarters · filed 2025-02-27 | $1.06M derived: sum of 3 quarters · filed 2025-02-27 | $1.30M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $412.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $650.00K derived: sum of 2 quarters · filed 2025-02-27 | $888.00K derived: sum of 3 quarters · filed 2025-02-27 | $1.13M 10-K · filed 2025-02-27 |
| 2022-09-30 | $238.00K 10-Q · filed 2023-11-08 | $476.00K derived: sum of 2 quarters · filed 2023-11-08 | $714.00K 10-Q · filed 2023-11-08 | $886.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $238.00K 10-Q · filed 2023-08-09 | $476.00K 10-Q · filed 2023-08-09 | $648.00K derived: sum of 3 quarters · filed 2024-02-29 | $788.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $238.00K 10-Q · filed 2023-05-09 | $410.00K derived: sum of 2 quarters · filed 2024-02-29 | $550.00K derived: sum of 3 quarters · filed 2024-02-29 | $690.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $172.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $312.00K derived: sum of 2 quarters · filed 2024-02-29 | $452.00K derived: sum of 3 quarters · filed 2024-02-29 | $591.00K 10-K · filed 2024-02-29 |
| 2021-09-30 | $140.00K 10-Q · filed 2022-11-08 | $280.00K derived: sum of 2 quarters · filed 2022-11-08 | $419.00K 10-Q · filed 2022-11-08 | $544.00K derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $140.00K 10-Q · filed 2022-08-09 | $279.00K 10-Q · filed 2022-08-09 | $404.00K derived: sum of 3 quarters · filed 2023-03-01 | $555.00K derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $139.00K 10-Q · filed 2022-05-10 | $264.00K derived: sum of 2 quarters · filed 2023-03-01 | $415.00K derived: sum of 3 quarters · filed 2023-03-01 | $566.00K derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $125.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $276.00K derived: sum of 2 quarters · filed 2023-03-01 | $427.00K derived: sum of 3 quarters · filed 2023-03-01 | $536.00K 10-K · filed 2023-03-01 |
| 2020-09-30 | $151.00K 10-Q · filed 2021-11-10 | $302.00K derived: sum of 2 quarters · filed 2021-11-10 | $411.00K 10-Q · filed 2021-11-10 | $519.00K derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $151.00K 10-Q · filed 2021-08-11 | $260.00K 10-Q · filed 2021-08-11 | $368.00K derived: sum of 3 quarters · filed 2021-08-11 | $477.00K derived: sum of 4 quarters · filed 2021-08-11 |
| 2020-03-31 | $109.00K 10-Q · filed 2021-05-11 | $217.00K derived: sum of 2 quarters · filed 2021-05-11 | $326.00K derived: sum of 3 quarters · filed 2021-05-11 | $435.00K derived: sum of 4 quarters · filed 2021-05-11 |
| 2019-12-31 | $108.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $217.00K derived: sum of 2 quarters · filed 2021-03-01 | $326.00K derived: sum of 3 quarters · filed 2021-03-01 | $436.00K 10-K · filed 2021-03-01 |
| 2019-09-30 | $109.00K 10-Q · filed 2020-11-05 | $218.00K derived: sum of 2 quarters · filed 2020-11-05 | $328.00K 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $109.00K 10-Q · filed 2020-08-06 | $218.00K 10-Q · filed 2020-08-06 | ||
| 2019-03-31 | $109.00K 10-Q/A · filed 2020-05-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 |